Filing Flows › Comparisons › STOK vs LXRX
Stoke Therapeutics vs Lexicon Pharmaceuticals: STOK and LXRX compared
Stoke Therapeutics is the larger company: $11.3M of revenue in its latest quarter (Q3 2026) against $11.2M for Lexicon Pharmaceuticals (Q3 2026). Stoke Therapeutics is growing faster (+6% against -21% a year earlier). Lexicon Pharmaceuticals is more profitable, with an operating margin of -128.8% against -686.9%.
Where the money goes: STOK and LXRX
Stoke Therapeutics (STOK) · Q3 2026
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
Lexicon Pharmaceuticals (LXRX) · Q3 2026
Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%, net loss $14.0M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
| Stoke Therapeutics (STOK) | Lexicon Pharmaceuticals (LXRX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $11.3M | $11.2M |
| Revenue growth, Y/Y | +6% | -21% |
| Operating margin | -686.9% | -128.8% |
| Net earnings | −$73.6M | −$14.0M |
| Net margin | -654.3% | -124.5% |
| Operating cash flow | −$62.7M | −$8.1M |
Questions
Which is bigger, Stoke Therapeutics or Lexicon Pharmaceuticals?
Stoke Therapeutics is the larger company: $11.3M of revenue in its latest quarter (Q3 2026) against $11.2M for Lexicon Pharmaceuticals (Q3 2026).
Is Stoke Therapeutics or Lexicon Pharmaceuticals growing faster?
Stoke Therapeutics is growing faster (+6% against -21% a year earlier).
Which is more profitable, Stoke Therapeutics or Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals is more profitable, with an operating margin of -128.8% against -686.9%.
More: Stoke Therapeutics earnings · how Stoke Therapeutics makes money · Lexicon Pharmaceuticals earnings · how Lexicon Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.